BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 19573808)

  • 1. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.
    Miao H; Li DQ; Mukherjee A; Guo H; Petty A; Cutter J; Basilion JP; Sedor J; Wu J; Danielpour D; Sloan AE; Cohen ML; Wang B
    Cancer Cell; 2009 Jul; 16(1):9-20. PubMed ID: 19573808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
    Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
    Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.
    Gopal U; Bohonowych JE; Lema-Tome C; Liu A; Garrett-Mayer E; Wang B; Isaacs JS
    PLoS One; 2011 Mar; 6(3):e17649. PubMed ID: 21408136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
    Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
    Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
    Shang X; Lin X; Howell SB
    Cell Commun Signal; 2014 Oct; 12():59. PubMed ID: 25344320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.
    Tawadros T; Brown MD; Hart CA; Clarke NW
    Br J Cancer; 2012 Nov; 107(10):1737-44. PubMed ID: 23037715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties.
    Miao H; Gale NW; Guo H; Qian J; Petty A; Kaspar J; Murphy AJ; Valenzuela DM; Yancopoulos G; Hambardzumyan D; Lathia JD; Rich JN; Lee J; Wang B
    Oncogene; 2015 Jan; 34(5):558-67. PubMed ID: 24488013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cataract mutations in EPHA2 SAM domain alter receptor stability and function.
    Park JE; Son AI; Hua R; Wang L; Zhang X; Zhou R
    PLoS One; 2012; 7(5):e36564. PubMed ID: 22570727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2.
    Kawai H; Kobayashi M; Hiramoto-Yamaki N; Harada K; Negishi M; Katoh H
    FEBS Open Bio; 2013; 3():78-82. PubMed ID: 23772378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
    Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
    Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serine 897 Phosphorylation of EPHA2 Is Involved in Signaling of Oncogenic ERK1/2 Drivers in Thyroid Cancer Cells.
    Allocca C; Cirafici AM; Laukkanen MO; Castellone MD
    Thyroid; 2021 Jan; 31(1):76-87. PubMed ID: 32762307
    [No Abstract]   [Full Text] [Related]  

  • 14. Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer.
    Efazat G; Novak M; Kaminskyy VO; De Petris L; Kanter L; Juntti T; Bergman P; Zhivotovsky B; Lewensohn R; Hååg P; Viktorsson K
    Oncotarget; 2016 Sep; 7(37):60332-60347. PubMed ID: 27533087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
    Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
    Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
    Cui XD; Lee MJ; Kim JH; Hao PP; Liu L; Yu GR; Kim DG
    Hepatology; 2013 Jun; 57(6):2248-60. PubMed ID: 23315987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.
    Fang WB; Brantley-Sieders DM; Hwang Y; Ham AJ; Chen J
    J Biol Chem; 2008 Jun; 283(23):16017-26. PubMed ID: 18387945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EPHA2 Promotes the Invasion and Migration of Human Tongue Squamous Cell Carcinoma Cal-27 Cells by Enhancing AKT/mTOR Signaling Pathway.
    Wang F; Zhang H; Cheng Z
    Biomed Res Int; 2021; 2021():4219690. PubMed ID: 33834064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphA2/Ephrin-A1 signaling complexes restrict corneal epithelial cell migration.
    Kaplan N; Fatima A; Peng H; Bryar PJ; Lavker RM; Getsios S
    Invest Ophthalmol Vis Sci; 2012 Feb; 53(2):936-45. PubMed ID: 22247486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.